N6-methyladenosine (m6A) in cancer therapeutic resistance: Potential mechanisms and clinical implications
Cancer therapy resistance (CTR) is the development of cancer resistance to multiple therapeutic strategies, which severely affects clinical response and leads to cancer progression, recurrence, and metastasis. N6-methyladenosine (m6A) has been identified as the most common, abundant, and conserved i...
Main Authors: | Dong Wang, Yan Zhang, Qingbo Li, Ao Zhang, Jingxuan Xu, Yu Li, Wen Li, Lin Tang, Fan Yang, Jingyan Meng |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-11-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223012751 |
Similar Items
-
Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance
by: Hong Lin, et al.
Published: (2022-07-01) -
Role of N6-methyladenosine modification in central nervous system diseases and related therapeutic agents
by: Junya Lv, et al.
Published: (2023-06-01) -
The roles of RNA N6-methyladenosine in esophageal cancer
by: Chuan Teng, et al.
Published: (2022-11-01) -
Research progress on the role of N6-methyladenosine (m6A) RNA modification in reproductive system diseases
by: ZHANG Yan, ZHU Meng-wen, LIU Tong, YANG Sheng, LIANG Ge-yu
Published: (2021-09-01) -
Multilevel regulation of N6-methyladenosine RNA modifications: Implications in tumorigenesis and therapeutic opportunities
by: Lili Feng, et al.
Published: (2023-09-01)